hengrui glp-1 glp 1 BMS signs $15.2bn R&D alliance with China's Hengrui Hengrui Pharma and Kailera Therapeutics

This extended-release delivery not only improves glycemic control but also enhances patient adherence by reducing the injection frequency from twice daily to once weekly

Pancreas 2021

This matters because the formulation determines the frequency

creatine, magnesium, electrolytes, and a short list of tested-deficiency vitamins come second

Finally, the potential effectiveness of new generation GLP-1 RA in terms of the dose- and exposure time-response still deserves further explorations

All of the dynamics around GLP-1s, compounding shortage workarounds, and potential for DTC telehealth fallout I described last August seem to be playing out in 2025